175 results on '"Rasmussen, Henrik S"'
Search Results
2. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval
3. Lirentelimab for severe and chronic forms of allergic conjunctivitis
4. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria
5. Batimastat and Marimastat in Cancer : Summary of Early Clinical Data
6. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial
7. New Agents for Hyperkalemia
8. Sodium Zirconium Cyclosilicate in Hyperkalemia
9. Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial
10. Fr198 GASTRODUODENAL EOSINOPHILIA IS UNDER-APPRECIATED IN EOSINOPHILIC ESOPHAGITIS (EOE) PATIENTS WITH FUNCTIONAL BOWEL SYMPTOMS: A REAL LIFE EXPERIENCE
11. Fr178 ACTIVATED MAST CELLS AND EOSINOPHILS ARE ASSOCIATED WITH INCREASED INFLAMMATORY MEDIATORS IN MUCOSAL BIOPSIES FROM PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS
12. 537 ENDOSCOPY AND SYSTEMATIC BIOPSY OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS LEADS TO HIGH DISCOVERY RATE OF PATIENTS WHO MEET HISTOLOGIC CRITERIA FOR EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS
13. Fr173 OPTIMIZATION OF EOSINOPHILIC GASTRITIS/DUODENITIS DETECTION REQUIRES EVALUATION OF MULTIPLE HIGH-POWERED FIELDS IN EACH OF 8 GASTRIC AND 4 DUODENAL BIOPSIES: ANALYSIS FROM A RANDOMIZED TRIAL
14. 539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8
15. Fr176 ENDOSCOPIC APPEARANCE DOES NOT PREDICT THE PRESENCE OF HISTOLOGIC EOSINOPHILIC GASTRITIS AMONG SYMPTOMATIC ADULTS, INDICATING THAT COLLECTION AND EVALUATION OF BIOPSIES SHOULD OCCUR REGARDLESS OF ENDOSCOPIC APPEARANCE: ANALYSIS FROM A RANDOMIZED TRIAL
16. Fr191 EOSINOPHILIC GASTRITIS AND EOSINOPHILIC DUODENITIS EXHIBIT A SIMILAR CLINICAL PRESENTATION, UNDERSCORING THE NEED FOR COLLECTION OF MULTIPLE BIOPSIES FROM BOTH THE STOMACH AND DUODENUM TO EVALUATE FOR TISSUE EOSINOPHILIA: ANALYSIS FROM A RANDOMIZED TRIAL
17. Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
18. S1330 High Discovery Rate of Previously Undiagnosed Patients With Eosinophilic Gastritis and Duodenitis Using a Systematic Endoscopic Biopsy Protocol: Screening Data Analysis From ENIGMA, a Randomized Controlled Trial
19. S3146 Patients With Eosinophilic Esophagitis (EoE) and Persistent Extra-Esophageal GI Symptoms Should Be Evaluated for Eosinophilic Gastritis (EG) and Eosinophilic Duodenitis (EoD)
20. Mo1236 MAST CELL LEVEL AND CLINICAL CORRELATES IN PATIENS WITH EOSINOPHILIC GASTRITIS AND GASTROENTERITIS
21. Tu1251 MAST CELLS ARE SIGNIFICANTLY ACTIVATED IN PATIENTS WITH ULCERATIVE COLITIS AND ARE INHIBITED BY AN ANTI-SIGLEC-8 ANTIBODY, ANTOLIMAB (AK002)
22. 932 HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE FORMS OF EOSINOPHILIC GASTROINTESTINAL DISEASES IN ENIGMA, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTOLIMAB (AK002)
23. Mo1237 ESTABLISHMENT OF NORMAL TISSUE MAST CELL LEVELS IN GASTRIC AND DUODENAL BIOPSIES OF PATIENTS WTHOUT GASTROINTESTINAL DISEASE
24. 867 EGID BIOPSIES HAVE FUNCTIONALLY DISTINCT AND ACTIVATED MAST CELLS THAT CONTRIBUTE TO DISEASE PATHOGENESIS AND ARE INHIBITED BY AN ANTI-SIGLEC-8 ANTIBODY, ANTOLIMAB (AK002)
25. 278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS
26. 228 INTERIM RESULTS OF AN OPEN-LABEL EXTENSION STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC ENTERITIS
27. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Pilot Study of the Safety and Feasibility of Catheter-Based Intramyocardial Injection of AdVEGF121 in Patients With Refractory Advanced Coronary Artery Disease
28. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis
29. 1244 Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Enteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia: A New Diagnostic Entity?
30. 1247 Development of a Patient Reported Outcome (PRO) Questionnaire to Assess the Symptoms of Eosinophilic Gastritis and Gastroenteritis (EG/EGE-SQ©)
31. 1246 Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis
32. Mo1163 – Eg and Eoe Patient Biopsies Have High Numbers of Activated Eosinophils and Mast Cells that are Inhibited by Ak002
33. Mo1127 – Mast Cells in Addition to Eosinophils are Markedly Elevated At Baseline in Patients with Eosinophilic Gastritis And/Or Gastroenteritis
34. Radiation-induced tumour necrosis factor-α expression: clinical application of transcriptional and physical targeting of gene therapy
35. Looking into anti-angiogenic gene therapies for disorders of the eye
36. Influence of Oral Magnesium Supplementation on Cardiac Events Among Survivors of an Acute Myocardial Infarction.
37. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
38. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
39. Siglec—8, a Novel Selective Target for Eosinophilic Gastrointestinal Diseases (EGIDs) Found on Eosinophils and Mast Cells in Human Tissue
40. A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects
41. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter
42. Maintenance of normokalemia with sodium zirconium cyclosilicate (ZS-9) in patients with heart failure on RAAS inhibitors: Subgroup analysis of a phase 3, randomized, placebo-controlled trial
43. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient
44. Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure
45. ACUTE-PHASE EFFICACY OF ZS-9 IN PATIENTS WITH BASELINE SERUM POTASSIUM LEVELS ABOVE 5.5 MEQ/L: ANALYSIS FROM A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL
46. TREATMENT OF HYPERKALEMIA WITH ZS-9, A SELECTIVE NONABSORBED CATION EXCHANGE RESIN, DOES NOT LEAD TO HYPOMAGNESEMIA: RESULTS FROM TWO MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS
47. ZS-9 MAINTAINS NORMOKALEMIA IN HYPERKALEMIC PATIENTS DESPITE CONTINUING RAAS INHIBITORS: A SUBGROUP ANALYSIS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL
48. Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap
49. Abstract 17489: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Achievement and Maintenance of K+ in Subgroup Analysis of Patients with Heart Failure not on RAAS Inhibitors
50. Batimastat and Marimastat in Cancer: Summary of Early Clinical Data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.